{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:39:04Z","timestamp":1792535944996,"version":"4.5.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"DOI":"10.1007\/s00408-026-00938-3","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:51:47Z","timestamp":1791017507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Author\u2019s Response to: Nebulised Heparin for Lung Disease: Three Overlooked Risks that Merit Study Before Chronic Clinical Use"],"prefix":"10.1007","volume":"204","author":[{"given":"Margarid","family":"Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank MP","family":"van Haren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","unstructured":"Fajar, F., & Haider, I. (2026). Nebulised heparin for lung disease: Three overlooked risks that merit study before chronic clinical use. Lung, 204(1). https:\/\/doi.org\/10.1007\/s00408-026-00937-4","DOI":"10.1007\/s00408-026-00937-4"},{"key":"938_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00408-026-00905-y","volume":"204","author":"M Miranda","year":"2026","unstructured":"Miranda M, Brown M, van Haren FMP, Brown B, Page CP (2026) Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies. Lung 204:44","journal-title":"Lung"},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","volume":"75","author":"J Hogwood","year":"2023","unstructured":"Hogwood J, Gray E, Mulloy B, Lever R, Page CP (2023) Pharmacology of heparin and related drugs: an update. Pharmacol Rev 75:328\u2013379","journal-title":"Pharmacol Rev"},{"key":"938_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1128\/AAC.20.2.155","volume":"20","author":"L Nilsson","year":"1981","unstructured":"Nilsson L, Maller R, Ansehn S (1981) Inhibition of aminoglycoside activity in heparin. Antimicrob Agents Chemother 20:155\u2013158","journal-title":"Antimicrob Agents Chemother"},{"key":"938_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40168-017-0265-7","volume":"5","author":"AA Heirali","year":"2017","unstructured":"Heirali AA, Workentine ML, Acosta N, Poonja A, Storey DG, Somayaji R, Rabin HR, Whelan FJ, Surette MG, Parkins MD (2017) The effects of inhaled aztreonam on the cystic fibrosis lung microbiome. Microbiome 5:51","journal-title":"Microbiome"},{"key":"938_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12931-019-1078-y","volume":"20","author":"P Rogliani","year":"2019","unstructured":"Rogliani P, Matera MG, Page CP, Puxeddu E, Cazzola M, Calzetta L (2019) Efficacy and safety profile of mycolytic\/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Resp Res 20:104","journal-title":"Resp Res"},{"issue":"2","key":"938_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1183\/09031936.06.00069005","volume":"27","author":"DJ Serisier","year":"2006","unstructured":"Serisier DJ, Shute JK, Hockey PM, Higgins B, Conway J, Carroll MP (2006) 354\u2013358 inhaled heparin in cystic fibrosis. ERJ 27(2):354\u2013358","journal-title":"ERJ"},{"issue":"1","key":"938_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1183\/09031936.01.17100360","volume":"17","author":"M Ledson","year":"2000","unstructured":"Ledson M, Gallagher M, Hart CA, Walshaw M (2000) Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients. Eur Resp J 17(1):36\u201338","journal-title":"Eur Resp J"},{"issue":"8","key":"938_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"K Richard","year":"2011","unstructured":"Richard K, Albert MD, Connett J, Bailey WC, Casaburi R, Cooper AD, Gerard J, Criner MC, Feffrey L, Curtis MD (2011) Azithromycin for prevention of exacerbations of COPD. New Engl J Med 365(8):689\u2013698","journal-title":"New Engl J Med"},{"issue":"1","key":"938_CR10","doi-asserted-by":"publisher","first-page":"13326","DOI":"10.1038\/s41598-023-40489-8","volume":"13","author":"R Ashmawy","year":"2023","unstructured":"Ashmawy R, Zaki A, Baess A, El Sayed I (2023) Efficacy and safety of inhaled heparin in asthmatic and chronic obstructive pulmonary disease patients: a systematic review. Sci Rep 13(1):13326","journal-title":"Sci Rep"},{"key":"938_CR11","doi-asserted-by":"crossref","unstructured":"Van Haren F, Valle SJ, Neto AS, Schultz MJ, Laffey JG et al (2025) Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVD-19: an investigator-initiated international meta-trial of randomised clinical studies. eClinical Med 88","DOI":"10.1183\/13993003.congress-2025.RCT2287"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00938-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00938-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00938-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:02:14Z","timestamp":1792533734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00938-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00938-3","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"2 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"76"}}